Immucor Completes Debt Restructuring

	Immucor, Inc. (NASDAQ: BLUD) is a leading supplier of diagnostic reagents and automated instrumentation to ensure the safety of blood transfusions
	TM Capital was retained by Immucor to assist in restructuring indebtedness following covenant defaults on Immucor's $42 million credit facility
	TM Capital assisted Immucor in negotiating a restructuring agreement which waived all defaults, eliminated a potential going concern qualification and minimized financing costs